sur Theranexus (EPA:ALTHX)
Industry stakeholders united to raise awareness of Batten disease
THX Pharma, Biocodex, and the Beyond Batten Disease Foundation announce their joint commitment as Platinum Sponsors of the BDSRA Annual Conference in 2026. This event, to be held in Chicago in July, will be an opportunity to present the progress of the Batten-1 program. This treatment, for Batten disease CLN3, is entering phase 3 clinical trials.
Every June 9th, International Batten Disease Awareness Day serves as a reminder of the challenges posed by this rare neurodegenerative disease. THX Pharma and its partners aim to facilitate access to innovative treatments to support affected families.
Their participation in the BDSRA conference underlines the importance of collaboration between researchers, clinicians and patient communities to advance the treatment of rare diseases.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus